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Abstract 
Background &Aims: Pruritus is a common symptom in patients with primary biliary cholangitis 
(PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. 
We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus 
and investigated the effect of GSK2330672, an IBAT inhibitor. 
Methods: We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC 
patients with pruritus at baseline and after two weeks of GSK2330672 treatment. Control group 
included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by 
ultraperformance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal 
microbiomes were analysed by 16S ribosomal RNA gene sequencing. 
Results: In PBC patients with pruritus serum levels of total and glyco-conjugated primary BAs 
and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- 
and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and 
after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- 
conjugated BAs and increased faecal levels of CA (p=0.048) and CDCA (p=0.027). Gut 
microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased 
relative abundance of Firmicutes (p=0.033) and Clostridia (p=0.04) and decreased Bacteroidetes 
(p=0.033) and Bacteroidia (p=0.04). 
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Conclusions: Pruritus in PBC does not show a distinct gut bacterial profile but is associated with 
elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic 
pruritus, a complex interplay between BAs and ATX is likely and may be modified by IBAT 
inhibition. 
Abstract word count: 250 words 
Keywords: pruritus, PBC, metabonome, microbiota 
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Lay summary  We compared serum bile acid, autotaxin and stool bacterial profile in PBC patients with and 
without itch and studied the effect of GSK2330672, a novel anti-pruritic drug. 
  In PBC patients with itch elevated levels of bile acids and autotaxin were found without any 
significant difference in the gut bacterial composition. 
  In PBC patients with itch GSK2330672 treatment decreased autotaxin and all major serum 
bile acids, increased faecal bile acids and changed gut bacterial composition. 
  Bile acids and/or autotaxin may have role in itch associated with PBC and they may be 
modified by GSK2330672 treatment to improve itch. 
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Introduction 
Primary biliary cholangitis (PBC) is a cholestatic liver disease, characterised by chronic 
inflammation and fibrotic destruction of interlobular bile ducts. If untreated, PBC may lead to 
biliary cirrhosis and need for liver transplantation.(1) Pruritus (itch) is a common and often a 
disabling symptom affecting up to 75% of patients at some point in their disease course.(2) It 
causes significant symptom burden and can produce a negative impact on health related quality 
of life.(2, 3) The anti-pruritic actions of bile acid (BA) sequestrants (e.g. colestyramine) point to 
potential role of BAs in the pathophysiology of cholestatic pruritus but the exact mechanism 
remains elusive.(4) Recent evidence shows serum autotaxin (ATX) activity is associated with 
cholestatic pruritus and its product lysophosphatidic acid (LPA) has been proposed as a 
candidate pruritogen in cholestasis.(5, 6) However, the relative contributions of ATX and total 
and individual BA species, and their mechanistic interactions in cholestatic pruritus remain 
obscure. 
The treatment of pruritus in PBC is challenging due to the limited efficacy and poor tolerability 
of currently available drugs and lack of effective new therapies. Ileal bile acid transporter 
(IBAT) inhibitor agents are emerging as potential novel therapy for pruritus in PBC.(7-10) 
Recently, we investigated GSK2330672, a novel, selective human IBAT inhibitor in a phase 2a, 
randomised controlled trial (RCT) and showed that PBC patients with pruritus receiving two 
weeks of oral treatment with GSK2330672 had significant improvement in their pruritus 
compared to placebo.(11)  
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Over the years, metabonomics has been applied to study the metabolic signatures in a variety of 
liver diseases.(12) There are limited studies in cholestatic liver diseases with metabonomic 
profiling of serum/plasma and urine from patients with PBC and primary sclerosing cholangitis 
(PSC) and none of these studies specifically investigated pruritus associated with cholestasis.(13-
16)  Also, the effect of anti-pruritic therapy on metabolites associated cholestatic pruritus has had 
only preliminary exploration in published abstract reports on the effect of bezafibrate and 
albumin dialysis.(17, 18) Moreover, the effect of IBAT inhibitor on the metabolites associated 
with pruritus is currently unknown.  
The role of gut microbiota in PBC is not clear. A recent study of patients with early-stage PBC 
reported alterations of the gut microbiome(19) and another study showed a distinct microbial 
diversity in ursodeoxycholic acid (UDCA)- treatment naïve PBC patients.(20) BAs modulate the 
gut microbiota and changes in intestinal BAs have been shown to significantly alter the 
composition of the gut microbiome in animal studies.(21) Also, the gut microbiota modulate the 
BA pool by metabolic deconjugation and transformation of primary BAs into secondary 
BAs.(22) Therefore, it is conceivable that in cholestatic pruritus, changes in BAs or microbiota 
or in the interaction of the two may have a role in the aetiology of the symptom, and may be 
modified by IBAT inhibition. However, to date, there are no studies reporting gut microbiota 
composition in patients with PBC and pruritus.  
The main aim of this study was to characterise the serum metabolite profile and the faecal 
microbial composition in PBC patients with pruritus. We set out to test the following hypotheses:  
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1) PBC patients with pruritus have a distinct serum metabonomic signature and gut microbiome 
composition, compared to PBC patients without pruritus and/or healthy people; and  
2) Pharmacological inhibition of enterohepatic circulation of BAs with an IBAT inhibitor can 
alter the serum and faecal BA profile, as well as change the faecal microbial composition in PBC 
patients with pruritus.  
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Materials and Methods 
Participants 
This prospective case-control study was carried out in two parts. In the first part, patients with 
PBC with pruritus were recruited to the BAT117213 study, a phase 2a, RCT of IBAT inhibitor 
GSK2330672. This RCT was sponsored by GlaxoSmithKline (GSK) and registered with 
EudraCT (2012-005531-84) and ClinicalTrials.gov (Identifier: NCT01899703). Ethical approval 
was given by the Research Ethics Committee NRES Committee North East – Sunderland 
(13/NE/0290). We recruited 22 PBC patients with pruritus between March 10, 2014, and Oct 7, 
2015. Itch severity was assessed using a 0-10 numerical rating scale (NRS), PBC-40 itch domain 
score and 5-D itch scale.(23, 24) The trial protocol is available online (7) and we have recently 
published the safety and efficacy data of GSK2330672 in PBC patients with pruritus.(11)  
In the second part, we recruited asymptomatic PBC patients (PBC-control) and healthy 
volunteers (HC). Participants in the PBC-control group were recruited only if they did not have 
any itch (assessed using PBC-40 itch domain score ≤3) and were not taking any anti-pruritic 
medications at the time of the study enrolment. Healthy volunteers who self-reported good health 
could enter the study when no known liver diseases were documented in their medical history. 
This study was sponsored by NIHR Newcastle BRC and approved by NRES Committee North 
East - Newcastle & North Tyneside 2 (14/NE/1036). PBC-control and HC were non-related, but 
were age (±2 years), gender and ethnicity matched to the PBC patients with pruritus of 
BAT117213 study. 
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The recruitment of participants in both studies occurred at two centres in the UK: Newcastle 
Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, and University Hospitals 
Birmingham NHS Foundation Trust, Birmingham. Informed consent was obtained from each 
patient included in the study and the study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki. 
Metabonomic analysis 
The BA profiling analysis in faecal samples was performed using a ‘semi-targeted’ profiling 
method, utilizing an ultraperformance liquid chromatography coupled to a quadrupole time-of-
flight mass spectrometry (UPLC-QToF-MS) assay at Imperial College London as previously 
reported.(25) In addition, quantitative measurements of up to 15 BAs in human serum was 
performed using Biocrates® Bile Acids Kit (BIOCRATES Life Sciences AG, Innsbruck, 
Austria). The assay was used with Waters Xevo® TQ MS triple quadrupole mass spectrometer 
(Waters Inc., Milford, Massachusetts, USA). Total bile acid (TBA) level was calculated by 
summation of 15 conjugated and unconjugated primary and secondary BA levels. We also used 
Biocrates AbsoluteIDQ® p150 kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) with 
Waters TQ-MS to quantify acylcarnitines, amino acids, glycerophospholipids and sphingolipids. 
Serum ATX assay was quantified as recently described.(26) Serum fibroblast growth factor 19 
(FGF19) was measured by a quantitative sandwich enzyme immunoassay technique according to 
the manufacturer’s instructions (Human FGF19, Quantikine® ELISA, R&D Systems, Oxford, 
UK). ATX and FGF19 assays were conducted in the Academic Medical Centre, Amsterdam. 
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Metataxonomic analysis 
We sequenced the V3-V4 region of the bacterial 16S ribosomal RNA (rRNA) gene to study the 
faecal bacterial composition in the study population. Sequencing was performed on the Illumina 
MiSeq platform (Illumina Inc., Saffron Walden, UK) using the MiSeq Reagent Kit v3 (Illumina) 
using paired-end 300bp chemistry. Further details of sample collection, preparation and 
statistical analysis of metabonomic and metataxonomic datasets are given in the supplementary 
information. 
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Results 
We studied data from 22 PBC patients with pruritus, 31 PBC patients without pruritus (PBC-
control) and 18 healthy volunteers (HC). None of the participants had taken any antibiotics for at 
least three months prior to study entry. The baseline demographic and clinical characteristics of 
the study groups are summarised in Table 1. The demographics and UDCA dose were 
comparable between PBC patients with pruritus and PBC-control. Serum levels of alkaline 
phosphatase (ALP), gamma-glutamyl transferase (GGT) and bilirubin and PBC-40 itch domain 
scores were significantly higher in PBC patients with pruritus compared to PBC-control.  
Bile acids and autotaxin in PBC with pruritus 
PBC patients with pruritus had significantly elevated total BA level compared to PBC-control 
and HC with glycocholic acid (GCA) and glycochenodeoxycholic acid (GCDCA) levels 
significantly higher than PBC-control (Table 2). There was no difference in the levels of UDCA 
or its conjugates between PBC patients with pruritus and PBC-control. 
In PBC patients with pruritus baseline serum ATX activity was significantly higher (Figure 1A) 
with mean serum level of total lysophosphatidylcholine (LPC) significantly lower (221±35.3 
µM) compared to HC (259±47.3 µM, p=0.04) but not PBC-control (231±57.2 µM, p=0.72).  
At baseline, 5-D itch scores significantly correlated with serum GCA (r=0.47, p=0.0257) and 
taurocholic acid [(TCA), r=0.45, p=0.0349] levels in PBC patients with pruritus (table S1). No 
significant correlations were seen between serum BAs, autotaxin and baseline PBC-40 itch 
domain score or NRS (tables S2&S3). 
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Analysis of other quantified serum metabolites showed significant differences in 43 metabolites 
between PBC patients with pruritus and HC (table S4). However, only one metabolite (C10:2, 
decadienylcarnitine) was significantly higher in PBC patients with pruritus (0.084±0.026 µM) 
compared to PBC-control (0.055±0.01 µM, p=0.013; Mann-Whitney test with FDR). 
IBAT inhibition reduces bile acids and autotaxin 
Serum and faecal BA profile data for pre- and post-GSK2330672 were available for 16 patients 
(samples from six patients were insufficient for analysis). Compared to the baseline, two weeks 
of GSK2330672 treatment significantly reduced serum levels of all tauro- and glyco-conjugated 
BAs (Table 3). Total BA level also decreased, but did not reach statistical significance 
(p=0.057). Serum levels of chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) 
significantly increased but cholic acid (CA) did not change significantly (p=0.78). GSK2330672 
treatment significantly decreased serum ATX activity levels (Figure 1B).  
Faecal BA profiling (n=14) showed significantly increased levels of total BA, CA, CDCA and 
DCA following GSK2330672 treatment, compared to the baseline (Figure 2). No significant 
differences were seen in other conjugated primary or secondary BAs (figure S1). 
Compared to the baseline, no significant changes were seen in other measured serum metabolites 
including acylcarnitines, glycerophospholipids or sphingolipids following GSK2330672 (data 
not shown).  
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Serum autotaxin correlates with bile acids 
 
In PBC patients with pruritus significant correlations were observed between conjugated primary 
and secondary BA levels and serum ATX activity at baseline (Table 4). Also, following 
GSK2330672 treatment percentage (%) changes (Δ) in serum ATX activity from baseline 
correlated significantly with %Δ in serum BA levels from baseline (Table 4). However, %Δ in 
serum BAs (total or individual) or ATX activity did not significantly correlate with %Δ in 5-D 
itch, PBC-40 itch domain or NRS cores (tables S5-7).  
Gut bacterial profile in PBC with pruritus 
The faecal bacterial composition of PBC patients with pruritus was not significantly different 
from the two control cohorts. Compositional analysis performed on phylum, class and order 
levels showed relative abundance of faecal bacteria from PBC patients with pruritus was not 
significantly different from those of PBC-control or HC (p>0.05 for all comparisons, ANOVA 
with Benjamini Hochberg FDR). Comparison of diversity indices showed no significant 
differences in the Chao1 index (p=0.051, Kruskal-Wallis test) or Shannon index (p=0.923, 
Kruskal-Wallis test) between study cohorts (figure S2). 
IBAT inhibition alters gut bacterial profile 
Gut bacterial composition of PBC patients with pruritus was compared at baseline and after 14 
days of treatment with GSK2330672 or placebo. For each subject, relative abundance of 
operational taxonomic units (OTUs) determined at the phylum level is shown in figure S3. A 
non-metric multidimensional scaling (NMDS) plot showed clear separation of bacterial 
composition after GSK2330672 treatment (figure S4A). Overall, GSK2330672 significantly 
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changed the bacterial community composition at the phylum level (PERMANOVA p=0.027), 
with a significant decrease in Bacteroidetes (p=0.033) and increase in Firmicutes (p=0.033) 
(figure S4B). Significant changes were also seen at the class and order levels with decrease in 
Bacteroidia (p=0.040) and Bacteroidales (p=0.011) and increase in Clostridia (p=0.040) and 
Clostridiales (p=0.044), respectively (figure S4C&D). No significant changes were seen at other 
taxonomic levels.  
Changes in faecal microbiota and faecal BA levels following GSK2330672 correlated with 
strongly positive correlation seen between phylum Firmicutes and CA (r=0.99) and CDCA 
(r=0.95) and negative correlation between phylum Bacteroidetes and CA (r=-0.74) and CDCA 
(r=-0.68) (figure S5). 
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Discussion 
We report the serum metabonomic profile and gut bacterial composition in PBC patients with 
pruritus and describe the effects of IBAT inhibition on serum and faecal BAs and compositional 
alterations in faecal bacteria in this patient group.  
In this study, we found altered serum BA profile in PBC patients with pruritus compared to PBC 
patients without pruritus. In addition to significantly higher levels of total BA, GCA and 
GCDCA, we observed GCA and TCA correlated with 5-D itch scores in PBC patients with 
pruritus. A recent trial of NGM282 (an engineered analogue of FGF19) also found significant 
association between baseline 5-D itch scores and serum GCA and TCA in patients with 
PBC.(27) We acknowledge that our cohort of PBC patients with pruritus had higher baseline 
levels of ALP, GGT and bilirubin but FGF19 levels were similar to PBC patients without 
pruritus. Since serum FGF19 levels are linked to the severity of cholestasis,(28) the latter is 
unlikely to have biased our serum BA results.  
We observed significant decrease in serum total and conjugated BAs following pharmacological 
IBAT inhibition with GSK2330672. In addition, we have recently reported that GSK2330672 
treatment significantly improved pruritus scores in PBC patients with pruritus.(11) Therefore, the 
anti-pruritic effect of an IBAT inhibitor agent could be mediated by reduction in circulating BAs. 
However, reductions in serum BAs did not correlate with reductions in pruritus scores. In a 
historic study fasting total BA levels were found to be higher in patients with pruritus compared 
to those without pruritus.(29) A positive relationship between pruritus and serum BAs has been 
shown(30) and improvement in pruritus with BA binding resin cholestyramine further supports 
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their role.(31) Taken together, our findings on differential BAs in PBC patients with pruritus and 
changes after IBAT inhibition therapy may suggest that serum (total or individual) BAs may 
have pathogenetic role in cholestatic pruritus.  
We also studied serum ATX which drives enzymatic conversion of LPC into LPA, a novel 
proposed pruritogen in cholestatic diseases.(6, 32) Similar to previous studies, we found elevated 
serum ATX activity in PBC patients with pruritus. Interestingly, we also observed correlations 
between serum BAs and ATX activity at baseline, with a strong correlation between GCDCA 
and ATX (r=0.80, p<0.0001). Also, reductions in tauro- and glyco-conjugated primary BAs and 
ATX levels after GSK2330672 treatment correlated significantly. Our observations on 
association between serum BAs and ATX are novel. This, in addition to the recent intriguing 
finding of the inhibitory effect of GCDCA on ATX activity (33) merits further investigation into 
the complex interplay between BAs and ATX in cholestatic pruritus. 
In the current literature there are only two reports on intestinal microbiota composition in PBC. 
In their study Lv et al. observed early stage PBC patients had reductions of several potentially 
beneficial gut microbiota (such as Acidobacteria, Lachnobacterium sp., etc.), and the enrichment 
of some opportunistic pathogens (such as γ-Proteobacteria, Enterobacteriaceae, etc.).(19)  Tang 
and co-workers observed reduced species richness and a lower level of microbial diversity in 
patients with PBC and partial restoration of these changes after UDCA treatment.(20) However, 
these investigators did not report gut microbiota in relation to pruritus associated with PBC. We 
hypothesized that pruritus in PBC is associated with specific gut bacterial dysbiosis. But our 
results did not show any significant difference in faecal bacterial composition or diversity 
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between PBC patients with pruritus compared to the control group. This lack of difference may 
suggest that cholestatic pruritus may not be associated with a specific gut bacterial composition. 
However, since we did not study functional alterations in the gut microbiota we cannot exclude 
the possibility of microbial metabolites contributing to cholestatic pruritus. Therefore, our 
negative findings on gut microbiota need to be confirmed in larger studies and additional studies 
are needed to investigate the role of gut microbial metabolites in cholestatic pruritus.  
Evidence suggest that BAs are important in regulating gut microbial community structure (34, 
35) and animal data show regulatory effects of gut microbiota on BA homeostasis.(36, 37) 
Although effects of IBAT inhibitor agents on serum and faecal BA levels have been studied in 
animal models of cholestasis,(38, 39) to date, there are no human studies on the effect of IBAT 
inhibition on the gut microbiota. We observed that in PBC patients with pruritus treated with an 
IBAT inhibitor agent faecal BA levels increased and faecal bacterial composition significantly 
changed from baseline. Increased faecal DCA levels could indicate increased conversion of CA 
to DCA by gut microbiota derived 7-α-dehydroxylase enzymes. Major taxonomic alterations 
were seen at the phylum, class and order-levels respectively, with significant decreases in 
Bacteroidetes, Bacteroidia and Bacteroidales and increases in Firmicutes, Clostridia and 
Clostridiales. We hypothesize that these changes are at least in part due to the direct effect of 
increased BA load in the colon resulting from IBAT inhibition. This idea is supported by 
increased faecal CA and CDCA levels after GSK2330672 and their strong correlations with 
Firmicutes and Bacteroidetes. Interestingly, our findings are similar to Islam and colleagues 
study, where rats fed with high CA diet showed significant expansions in Firmicutes (from 54% 
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to 93-98%) and Clostridia (from 39% to 70%) and significant inhibition of the 
Bacteroidetes.(21) However, an important question that remains unanswered by our study, but 
that merits further investigation is, whether the changes in the gut microbiome produced by the 
IBAT inhibitor contribute to its anti-pruritic effect in PBC via changes in faecal microbial 
metabolites.  
Although we have attempted to provide a comprehensive insight into the serum metabonome and 
gut microbiota in cholestatic pruritus, our study has limitations to be addressed in future studies. 
First, our relatively small cohort may have resulted in insufficient statistical power to unravel all 
metabolic perturbations. To determine the complete metabonome profile and microbial 
diversities, a large cohort of PBC patients with pruritus is required. Ongoing clinical 
development of GSK2330672 (NCT02966834) may present the opportunity for further study of 
metabonomic and microbiomic profile in cholestatic pruritus. Second, we did not investigate the 
metagenome (functional composition profile) of microbiota which may help in analysis of 
pathway(s) associated with cholestatic pruritus. Third, instead of mucosal microbiota we opted to 
study stool samples, but it is known that faecal bacterial profiles do not fully replicate mucosa 
associated profiles.(40) Also, we did not objectively assess stool consistency, which is recently 
shown to be strongly associated with gut microbiota composition.(41) Finally, although our 
cohort was matched for age, BMI and ethnicity, results could be influenced by other confounding 
effects such as environment and dietary factors. 
In summary, in PBC patients with pruritus we observed elevated serum bile acid and autotaxin 
levels which decreased after anti-pruritic treatment with an IBAT inhibitor agent. The strong 
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correlation between serum bile acids and autotaxin at baseline and post IBAT inhibition suggests 
a complex interplay between bile acids and autotaxin in cholestatic pruritus is likely and may be 
modified by IBAT inhibition to reduce pruritus. Gut bacterial composition of PBC patients with 
pruritus was not different from control but altered significantly following IBAT inhibition. Our 
findings need to be confirmed in future studies which should focus on further dissecting the 
underlying molecular mechanism of cholestatic pruritus and clarifying the mechanisms of the 
anti-pruritic effect of IBAT inhibitor agents. 
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Figure legends 
 
Figure 1 Serum autotaxin activity A) in study cohorts, and B) in PBC patients with pruritus at 
baseline and after treatment with GSK2330672. (Data in mean±SD; Unpaired t-test used in 
figure 1A and paired t-test in figure 1B). 
Figure 2 Faecal bile acid profile in PBC patients with pruritus at baseline and after treatment 
with GSK2330672. A) Total and B) individual bile acids. (Data in mean±SD. P values adjusted 
with FDR correction as described in method section). 
 
